Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006

Benjamin J Park1, Peter G Pappas, Kathleen A Wannemuehler

  • 1Centers for Disease Control and Prevention, Atlanta, Georgia, USA. bpark1@cdc.gov

Insights

Non-Aspergillus mold infections, including mucormycosis, are increasingly affecting transplant recipients and are linked to high mortality. Mucormycosis incidence rose significantly in hematopoietic cell transplant patients during 2001-2006.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Transplant Medicine

Background:

  • Increasing incidence of non-Aspergillus mold infections reported in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients.
  • Need for epidemiological data on infections caused by Mucorales, Fusarium spp., and Scedosporium spp. in transplant populations.

Purpose of the Study:

  • To investigate the epidemiology of non-Aspergillus mold infections, specifically Mucorales, Fusarium spp., and Scedosporium spp., in HCT and SOT recipients.
  • To determine the incidence and mortality rates associated with these infections.

Main Methods:

  • Analysis of data from the Transplant-Associated Infection Surveillance Network.
  • Prospective surveillance for invasive fungal infections across 23 transplant centers from 2001 to 2006.
  • Identification and classification of fungal pathogens, including Mucorales, Fusarium spp., and Scedosporium spp.

Main Results:

  • 169 infections identified in 169 patients: 105 Mucorales, 37 Fusarium spp., 27 Scedosporium spp.
  • 124 infections (73.4%) in HCT recipients, 45 infections (26.6%) in SOT recipients.
  • Crude 90-day mortality rate was 56.6%; 12-month mucormycosis incidence was 0.29% for HCT and 0.07% for SOT.
  • Mucormycosis incidence in HCT recipients increased during 2003-2004 and over the surveillance period.

Conclusions:

  • Non-Aspergillus mold infections remain a significant cause of mortality in transplant recipients.
  • The incidence of mucormycosis has substantially increased among HCT recipients.
  • Continued surveillance and research are crucial for managing these challenging infections.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...